C4 Therapeutics (CCCC) Short term Debt (2022 - 2023)
C4 Therapeutics' (CCCC) quarterly Short term Debt came in at $10.3 million in Q2 2023, up 1278.0% year-on-year from $750000.0 in Q2 2022, and up 351.9% quarter-over-quarter from $2.3 million in Q1 2023.
C4 Therapeutics (CCCC) Short term Debt (2022 - 2023) Analysis & Trends
C4 Therapeutics' Short term Debt history runs 2 years deep, the most recent figure standing at $10.3 million for Q2 2023.
- On a quarterly basis, Short term Debt rose 1278.0% year-over-year to $10.3 million in Q2 2023; TTM through Jun 2023 was $10.3 million, a 1278.0% increase from a year earlier, with the FY2022 full-year figure at $2.3 million, changed N/A from the prior year.
- Short term Debt climbed to $10.3 million in Q2 2023 per CCCC's latest filing, from $2.3 million in the prior quarter.
- Across five years, Short term Debt topped out at $10.3 million in Q2 2023 and bottomed at $750000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | C4 Therapeutics | 460.17 Mn | 224.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 10.34 Mn |
| Mar 31, 2023 | 2.29 Mn |
| Dec 31, 2022 | 2.29 Mn |
| Sep 30, 2022 | 2.25 Mn |
| Jun 30, 2022 | 750,000.00 |
| Mar 31, 2022 | 750,000.00 |